Sangamo and Astellas Announce Capsid License Agreement to Deliver Genomic Medicine for Neurological Diseases

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time   BRISBANE, Calif. --(BUSINESS WIRE)--May 4, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and first quarter 2021 financial results.